JOHN C. OLSON, M.D.

EDUCATION M.D. Honors Program in Medical Education March, 1977 Northwestern University Chicago, Illinois

B.S. Northwestern University June, 1975 Chicago, Illinois

FELLOWSHIP, RESIDENCY, INTERNSHIP Vitreoretinal Fellowship: Bascom Palmer Eye Institute 1981 - 1982 University of Miami Miami, Florida

Ophthalmology Residency: University of Texas 1978 - 1981 Health Science Center Dallas, Texas

Internship (Rotating): University of Texas 1977 - 1978 Health Science Center Dallas, Texas

MEDICAL PRACTICE Central Florida Retina Diseases & Surgery of the 1982 - Present 44 Lake Beauty Dr., Suite 300 Retina and Vitreous Orlando, FL 32806

HOSPITAL APPOINTMENTS Active, Ophthalmology: Orlando Regional Health System, Orlando, Florida 1982 - Present Florida Hospital, Orlando, Florida 1983 - Present Halifax Medical Center, Daytona Beach, Florida 1987 - Present Orlando Ophthalmology Surgery Center, Orlando, Florida 2003 - Present ACADEMIC APPOINTMENTS Assistant Professor of Ophthalmology 2010 - present College of Medicine University of Central Florida Orlando, Florida

CERTIFICATION American Board of Ophthalmology December, 1982

LICENSURE Texas February, 1978 Florida May, 1981

MEDICAL SOCIETIES Florida Society of Ophthalmology American Academy of Ophthalmology American Society of Retina Specialists

PRESENTATIONS 1. Olson, John C.: Results of Resident Intraocular Lens Surgery Veterans Administration Hospital, Dallas, Texas Presented at the University of Texas Health Science Center Resident and Alumni meeting, Dallas, Texas, June 1981

2. Olson, John C.: Results in the treatment of Postoperative Endophthalmitis Presented at the 87 Annual Meeting of the American Academy of Ophthalmology, San Francisco, California, October 30-Novemer 5, 1982

3. Olson, John C.: Update on Endophthalmitis Presented at the American Academy of Ophthalmology, Southern Regional Update Course, Miami, Florida, March 4, 1989

4. Olson, John C.: Retinal Hemorrhages as a Consequence of Epidural Steroid Injection Presented at the Bascom Palmer Eye Institute Anniversary Meeting in Honor of Donald Gass, M.D., Miami, Florida, May, 1995 PUBLICATIONS 1. Olson JC, Flynn HW, Jr, Forster RK, Culbertson WW. Results in the treatment of postoperative endophthalmitis. Ophthalmology. 1983:90(6):692–699.

2. Kushner, FH, Olson, JC. Retinal Hemorrhage as a Consequence of Epidural Steroid Injection. Arch Ophthalmology. 1995:113: 309-313.

3. Shaikh S, Ho S, Richmond PP, Olson JC, Barnes CD. Untoward Outcomes in 25-Gauge versus 20-Gauge Vitreoretinal Surgery. Retina 2007:27(8): 1048-1053.

4. Shaikh S, Olson JC, Richmond PP. Retinal Pigment Epithelial Tears after Intravitreal Bevacizum- ab Injection for Exudative Age-Related . Indian J Ophthalmol. 2007 Nov- Dec:55(6):470-2.

5. Griffen D, Richmond PP, Olson JC. Intravitreal Outcomes in Patients with Persistent Mac- ular Exudate Previously Treated with and/or for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology. 2014 Nov 20 (2014): 1-6.

RESEARCH 1. Miravant - Protocol #SnET2-98EA001; Principal Investigator A Phase III Randomized, Parallel-Group, Multicenter Study to Observe Lesion Response Efficacy over a 2-Year Study Period with SnET2-PDT Treatment of Subfoveal CNV Secondary to Age-Related Macular Degeneration.

2. New England Eye Center, Tufts University: TTT 4CNV; Principal Investigator Transpupillary Thermal Therapy in Age-Related Macular Degeneration.

3. Novartis Pharmaceutical - Protocol #CSMS995 0804; Principal Investigator A Phase II Randomized, Double-Masked, Controlled Study to Evaluate the Safety and Efficacy of Sandostatin (Octreotide) in Patients with Diabetic Macular Edema.

4. Alimera (FAME); Principal Investigator A Phase II Randomized, Double Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema.

5. Regeneron (VIEW); Principal Investigator A Phase III Randomized, Double Masked, Active Controlled Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age- Related Macular Degeneration.

6. Regeneron (VISTA) Protocol VGFT-OD-1009 DME; Principal Investigator A Double-Masked, Randomized, Active-Controlled, Phase III Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema.

7. Genentech; Protocol #FVF2587g ANCHOR; Sub-Investigator A Phase III Study which compares efficacy of subjects who have Lucentis®, injected into the eye once a month for two years, to PDT (Visudyne®), administered to the eye every three months for two years in patients with wet Age-Related Macular Degeneration (AMD). RESEARCH (cont.) 8. Genentech; Protocol #FVF3192g PIER; Sub-Investigator Age-Related Macular Degeneration Study.

9. DRCR network; Sub-Investigator A Phase II Study for Evaluation of Bevacizumab (Avastin) Intravitreal Injections in Subjects with Diabetic Macular Edema.

10. VERTACL Study; Sub Investigator A Phase II/III Multi-Center, Randomized, Clinical Trial to evaluate the Effects of Preservative- Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants with Neovascular Age-Related Macular Degeneration (AMD).

11. National Eye Institute: (SCORE) Study; Sub-Investigator Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion.

12. Alcon/Novartis; Sub-Investigator A Phase III Randomized, Parallel-Group, Multicenter, Double-Masked Study of the Safety and Efficacy of for Depot Suspension (15mg and 30 mg) Versus Sham Adminis- tration in Arresting the Progression of Non-Exudative (dry) AMD in Patients who are at Risk for Progressing to Exudative (wet) AMD.

MISCELLANEOUS Volunteer Medical Mission Project ORBIS Arequipa, Peru, 1983

Grace Medical Home Volunteer Physician Orlando, Florida, 2011 - present